Disruption of the precise balance of positive and negative molecular regulators of blood and lymphatic vessel growth can lead to myriad diseases. Although dozens of natural inhibitors of hemangiogenesis have been identified, an endogenous selective inhibitor of lymphatic vessel growth has not to our knowledge been previously described. We report the existence of a splice variant of the gene encoding vascular endothelial growth factor receptor-2 (Vegfr-2) that encodes a secreted form of the protein, designated soluble Vegfr-2 (sVegfr-2), that inhibits developmental and reparative lymphangiogenesis by blocking Vegf-c function. Tissue-specific loss of sVegfr-2 in mice induced, at birth, spontaneous lymphatic invasion of the normally alymphatic cornea and hyperplasia of skin lymphatics without affecting blood vasculature. Administration of sVegfr-2 inhibited lymphangiogenesis but not hemangiogenesis induced by corneal suture injury or transplantation, enhanced corneal allograft survival and suppressed lymphangioma cellular proliferation. Naturally occurring sVegfr-2 thus acts as a molecular uncoupler of blood and lymphatic vessels; modulation of sVegfr-2 might have therapeutic effects in treating lymphatic vascular malformations, transplantation rejection and, potentially, tumor lymphangiogenesis and lymphedema.
The blood and lymphatic vessel networks are jointly essential for development, wound healing and immune surveillance and activation. Pathological responses of these parallel circulatory systems can lead to diseases as varied as age-related macular degeneration, atherosclerosis, cancer, lymphedema, rheumatoid arthritis and tumor metastasis 1 . Collectively, exuberant or inadequate responses of hemangiogenesis and lymphangiogenesis are estimated to affect nearly two billion people worldwide 2, 3 . The prevalence of such diseases has fueled intense efforts to develop pro-and antiangiogenic therapeutics. Several antihemangiogenic drugs are US Food and Drug Administration-approved, but, to our knowledge, no lymphangiogenesis-specific inhibitor has yet entered clinical trials. As such, there is great interest in identifying such specific inhibitors both to alleviate disease burden and to better understand lymphatic vascular biology. However, it has been challenging to develop selective approaches toward modulating lymphangiogenesis due to the difficulty in mechanistically disassociating it from hemangiogenesis.
The Vegf family of molecules is indispensable for growth of blood 4, 5 and lymphatic 6 vessels. Hemangiogenesis is governed by a precise balance of positive and negative regulators 7 ; however, the mechanisms governing lymphangiogenesis remain nebulous. Soluble VEGFR-1 proteins generated by splice variants in the gene encoding VEGFR-1 act as potent natural inhibitors of hemangiogenesis by trapping the blood endothelial mitogen VEGF-A [8] [9] [10] . To our knowledge, other secreted forms of VEGF tyrosine kinase receptors resulting from splice variants have not been previously reported. Here we describe the detection and function of a new secreted VEGF receptor generated by alternative splicing, which we show is an endogenous antagonist of VEGF-C and a crucial regulator of lymphatic vessel growth.
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RESULTS

Cloning of sVegfr-2
During the course of our studies uncovering the nonredundant function of sVegfr-1 in corneal avascularity 11 , which is crucial for optimal vision, we observed, by western blotting, anomalous migration of a 75-kDa protein species that was immunoreactive to an antibody (T014; ref. 12 ) that recognizes the amino terminus of Vegfr-2 ( Supplementary Fig. 1a ). Given the similarity in the exon-intron structure between Vegfr1 (official symbol Flt1) and Vegfr2 (official symbol Kdr), we hypothesized that this unidentified protein represented a previously undescribed truncated form of the 230-kDa membrane-bound form of Vegfr-2 (mbVegfr-2) resulting from alternative splicing. Given that the lymphatic mitogen VEGF-C (ref. 13 ) is capable of binding mbVEGFR-2 (ref. 14) , a truncated form of Vegfr-2 might have antilymphangiogenic activity.
We modeled the potential alternative splicing of Vegfr2 on the basis of the alternative splicing that occurs in Vegfr1 (ref. 8) , and found that retention of intron 13 in the mature messenger RNA would yield a truncated transcript variant whose protein product would lack the transmembrane and intracellular tyrosine kinase domains of mbVegfr-2, owing to the presence of an in-frame termination TAA codon 39 nucleotides downstream from the exon 13-intron 13 junction ( Supplementary Fig. 1c) . To verify the existence of this soluble splicing variant in the mouse cornea, we devised primers targeting intron 13 and exon 12 ( Supplementary Fig. 1c and Supplementary   Fig. 2a ). Use of an exon 12-targeted primer allowed us to distinguish between amplification of mRNA-derived complementary DNA and genomic DNA contamination on the basis of amplicon size. PCR yielded a 393-base pair product spanning the location of the splicing event (Supplementary Fig. 1d ). Bioinformatic analysis of intron 13 revealed three potential polyadenylation (polyA) signal sequences ( Supplementary Fig. 1c ). Using rapid amplification of cDNA 3′ ends PCR, we found the third potential polyA signal at positions 3,956-3,961 to be functional ( Supplementary Fig. 1c,e and Supplementary  Fig. 2a ). From mouse corneal mRNA, we cloned a cDNA containing a 2,022-base pair open reading frame encoding a polypeptide of 673 amino acids designated as sVegfr-2 ( Supplementary Fig. 2b ; the sequence of the sVegfr2 transcript is shown in Supplementary  Fig. 2a ). This protein contains a 13-amino acid carboxyl-terminus sequence ( Supplementary Fig. 1b ) not present in mbVegfr-2 or in any other known protein and against which we raised a rabbit polyclonal antibody (AA21127; Supplementary Fig. 3 ).
sVegfr-2 is expressed in and is essential for alymphatic cornea
This sVegfr2 transcript was localized by in situ hybridization principally to the corneal epithelium ( Fig. 1a) . Immunolocalization using the AA21127 antibody in the newborn mouse showed the presence of sVegfr-2 in the corneal epithelium and stroma ( Supplementary  Fig. 4a ). In the adult cornea, sVegfr-2 was more abundant in the epithelium than in the stroma ( Fig. 1b and Supplementary Fig. 4a ). sVegfr-2 was distributed uniformly in the cornea with enhanced expression near the limbus (Supplementary Fig. 4b) . In contrast, sVegfr-2 did not immunolocalize in the conjunctiva (Supplementary Fig. 4b,c) . We identified sVegfr-2 in the cornea as a 75-kDa species by western blotting using both the AA21127 and T014 antibodies ( Supplementary  Fig. 4d ). However, we did not detect the 230-kDa mbVegfr-2 in the cornea by western blotting with T014 ( Supplementary Fig. 1a ) or by immunofluorescence with an antibody targeting the carboxyl terminus Fig. 4e ). Neither did we detect the mbVegfr2 transcript in the cornea by RT-PCR ( Supplementary Fig. 4f ). Thus, the mouse cornea expresses sVegfr-2 but not mbVegfr-2.
To define the function of sVegfr-2 in the cornea, we targeted it using multiple strategies. Because Vegfr2 −/− mice die in utero 15 , we ablated corneal sVegfr-2 expression using a Cre-loxP strategy. This strategy enabled the specific targeting of sVegfr-2, because mbVegfr-2 is not expressed in the cornea ( Supplementary Fig. 4e ,f). We created Vegfr2 loxP/loxP mice by targeting exon 1 (Supplementary Fig. 5 ) and interbred them with LeCre mice that constitutively and uniformly express Cre recombinase in the cornea under the control of a paired box-6 promoter 16 . Mice of all genotypes were born at the expected mendelian ratios and were macroscopically indistinguishable from one another. However, all LeCre;Vegfr2 loxP/loxP mouse corneas (n = 30), which lacked sVegfr-2 expression ( Supplementary  Fig. 6a ), were densely covered with lymphatic vessels at postnatal day 0 (P0) ( Fig. 1c) . We identified these vessels as lymphatics by virtue of their intense lymphatic vessel endothelial receptor-1 (Lyve-1) reactivity, moderate CD31 reactivity, nuclear prospero homeobox-1 (Prox1) expression and blind-ended morphology (Fig. 1c-e and Supplementary Fig. 6b ). Although Lyve-1 + macrophages have been described in the cornea 17 , coexpression of Prox1 in these vessels confirmed their identity as lymphatics ( Fig. 1d,e ). Furthermore, ultrastructural examination showed that these vessels lacked erythrocytes, did not have a continuous basement membrane and contained partly overlapping thin endothelial cells free of pericyte coverage-all features typical of lymphatics ( Fig. 1f) . Because the growth of blood and lymphatic vessels is usually intertwined, we found it surprising that these corneas were not invaded by blood vessels, as indicated by the absence of CD31 + Lyve-1 − vessels ( Fig. 1c,g) . We confirmed this independently by demonstrating that the vessels in these corneas did not express MECA-32, a blood vessel-specific marker ( Supplementary  Fig. 6c,d) . All littermate control corneas (n = 30) were, like those of wild-type mice, devoid of both lymphatic and blood vessels ( Fig. 1c and Supplementary Fig. 6d ). LeCre;Vegfr2 loxP/loxP mice had normal limbal blood vessel morphology and an unimpaired corneal hemangiogenesis response to suture injury ( Supplementary Fig. 6d,e ), confirming intact vascular endothelial cell Vegfr-2 function.
sVegfr-2 is a Vegf-c antagonist
These results indicate that the developing mouse cornea is exposed to prolymphangiogenic stimuli that are counterbalanced by sVegfr-2 to create an alymphatic cornea. Indeed, wild-type P0 corneas, unlike adult corneas, showed Vegf-c expression ( Supplementary Fig. 7 ). We reasoned that sVegfr-2 ablation led to spontaneous corneal lymphangiogenesis because of the ability of sVegfr-2 to bind Vegf-c and thereby inhibit its function. Indeed, the amounts of sVegfr-2 (1,655.8 ± 44.62 pg per mg of total protein) in wild-type P0 cornea were sufficiently in excess of Vegf-c (45.4 ± 3.2 pg per mg of total protein) to fulfill a trapping function. sVegfr-2, which contains the Vegf-c-binding immunoglobulin-like domain-2 of mbVegfr-2 (ref. 18) , interacted with Vegf-c, as determined by immunoprecipitation, and inhibited both Vegfr-3 phosphorylation and proliferation of lymphatic endothelial cells (LECs) stimulated by VEGF-C ( Fig. 1h-j) . Also, Vegf-c-induced corneal lymphangiogenesis was inhibited by intracorneal administration 11 of a plasmid encoding sVegfr-2 (psVegfr-2) ( Supplementary Fig. 8 ). Collectively, these data are consistent with a model in which sVegfr-2 acts as an endogenous sink for Vegf-c during corneal development and thereby establishes an alymphatic cornea.
Consistent with the report that mouse Vegfr-2 binds human VEGF-D but not mouse Vegf-d (ref. 19 ), psVegfr-2 inhibited corneal lymphangiogenesis induced by human VEGF-D but not mouse Vegf-d ( Supplementary Fig. 8 ). Also, unlike Vegf-c, Vegf-d was not expressed in the newborn mouse cornea ( Supplementary Fig. 9 ), consistent with the idea that sVegfr-2 maintains the alymphatic nature of the cornea. 
inhibits lymphangiogenesis and transplant rejection
To determine the function of sVegfr-2 in the adult, we studied a clinically relevant mouse model of suture-induced corneal neovascularization 20 . Suture injury increased corneal sVegfr-2 expression (in the epithelium but not in infiltrating macrophages) in wild-type mice (Supplementary Fig. 10 ). Ablation of sVegfr-2 expression by intracorneal administration 11 of a plasmid coding for Cre recombinase (pCre) in Vegfr2 loxP/loxP mice markedly increased sutureinduced lymphangiogenesis but not hemangiogenesis compared to empty vector (pNull) administration by 161% ± 9% (P < 0.05, n = 5 mice per group) ( Fig. 2a-c) . This outstripping of hemangiogenesis by lymphangiogenesis suggests that induction of endogenous sVegfr-2 expression by injury is a compensatory antilymphangiogenic response. Both pCre-injected and pNull-injected corneas of wildtype mice showed similar degrees of lymphangiogenesis after suture injury, excluding a nonspecific effect of Cre recombinase (Fig. 2c) . pCre-induced enhancement of suture-induced lymphangiogenesis in Vegfr2 loxP/loxP mice was reduced by a Vegfr-3 tyrosine kinase inhibitor 21 , supporting the concept that endogenous sVegfr-2 is an in vivo Vegf-c antagonist ( Fig. 2c) . Conversely, augmentation of sVegfr-2 expression using in vivo transfection 11 of wild-type mouse corneas with psVegfr-2, but not pNull, reduced suture injury-induced lymphangiogenesis but not hemangiogenesis by 76% ± 6% (P < 0.05, n = 5 mice per group) ( Fig. 2d,e ).
Because lymphangiogenesis has been implicated in corneal allograft rejection 22 , we studied the function of sVegfr-2 in a mouse model of corneal transplantation. A single intracorneal administration of a dimeric Vegfr-2-Fc fusion protein more than doubled the transplant survival rate (a 105% and 101% increase compared to IgG-Fc and no treatment, respectively; P < 0.05, n = 10-13 mice per group; Fig. 2f ). The markedly lower rejection rate induced by Vegfr-2-Fc administration (75% compared to IgG-Fc treatment and 74% compared to no treatment) is consistent with the observed reduction in blood vessel and lymphatic sprouting through the donor-recipient interface (Fig. 2g,h) . To our surprise, a single intracorneal administration of monomeric sVegfr-2 induced the same degree of corneal allograft survival as did dimeric Vegfr-2-Fc, despite reducing sprouting of only lymphatic vessels through the donor-recipient interface (blood vessels were not affected; Fig. 2f-h) . These data suggest that inhibition of lymphatic vessels impairs the establishment of the draining route through which immune cells are trafficked [23] [24] [25] and is sufficient to enhance corneal allograft survival.
Endogenous Vegf-c promotes lymphangiogenesis
Selective lymphangiogenesis inhibition by sVegfr-2 is consistent with the selective effect of endogenous Vegf-c on the lymphatic vasculature 6, 13, [26] [27] [28] . However, implantation of pellets containing 160-200 ng of recombinant human VEGF-C into the mouse cornea has been reported to induce hemangiogenesis [29] [30] [31] [32] . To reconcile these findings, we injected neutralizing Vegf-c-specific antibodies into the corneas of wild-type mice after suture injury and found that this resulted in inhibition of lymphangiogenesis (P < 0.05, n = 8) but not hemangiogenesis (Fig. 3a,b) . These data show that endogenous Vegf-c selectively promotes lymphangiogenesis in the cornea and help explain the selective effect of sVegfr-2. The lack of Vegfr-3 expression in conjunctival and corneal blood vessels 33, 34 also supports a model in which endogenous Vegf-c binds Vegfr-3 on lymphatic vessels preferentially compared to Vegfr-2 on blood vessels in these tissues on the basis of relative receptor affinities 35 . Also, Vegf-c is far less efficient at activating Vegfr-2 than is Vegf-a 36 , the principal driver of corneal hemangiogenesis 11, 32 . We quantified VEGF-C abundance after implanting a 160-ng VEGF-C pellet and found that this resulted in corneal VEGF-C levels that were 100-125 times greater than those observed after suture injury and 45-66 times greater than levels in neonatal corneas (Fig. 3c) . Such exaggerated amounts of VEGF-C, which are supraphysiological and far greater than those achieved in pathophysiologically relevant states, could explain the reported hemangiogenic effects of exogenous VEGF-C.
Monomeric sVegfr-2 does not block hemangiogenesis
The selective effect of sVegfr-2 in inhibiting lymphangiogenesis but not hemangiogenesis was unexpected, because mbVegfr-2 is capable of binding Vegf-a, which promotes hemangiogenesis. To explain this selectivity, we first sought to determine whether sVegfr-2 exists in monomeric or dimeric form, because a recombinant form of the ectodomain of mbVEGFR-2 has been shown to be a monomer that has little or no affinity for VEGF-A compared to a dimeric recombinant VEGFR-2-Fc fusion protein [37] [38] [39] . We found that sVegfr-2 secreted by mouse corneal epithelial cells, human embryonic kidney cells and Chinese hamster ovary cells, as well as recombinant sVEGFR-2, all migrated at equivalent apparent molecular masses under both nonreducing and reducing conditions of western blotting, data consistent with its existence as a monomer (Fig. 3d,e) . In contrast, the migration of VEGFR-2-Fc was consistent with it being a dimer (Fig. 3e ).
Next, we tested the effects of monomeric sVegfr-2 and dimeric Vegfr-2-Fc on models of corneal neovascularization induced by injury or Vegf-a treatment. Suture-induced corneal hemangiogenesis, which is driven principally by upregulation of endogenous Vegf-a 32 , was inhibited by Vegfr-2-Fc but not sVegfr-2 (Fig. 3f) . Similarly, VEGF-A-induced phosphorylation of mbVEGFR-2 in porcine aortic endothelial cells was inhibited by VEGFR-2-Fc but not sVEGFR-2, and Vegf-a-induced corneal hemangiogenesis was inhibited by Vegfr-2-Fc but not by sVegfr-2 or psVegfr-2 (Fig. 3g,h) . These functional data provide a mechanistic basis for the absence of an antihemangiogenic effect of endogenous sVegfr-2 and corroborate the previously reported in vitro differential VEGF-A binding avidity between monomeric and dimeric forms of VEGFR-2.
Nonocular role of sVegfr-2
We detected sVegfr2 mRNA expression by northern blotting of poly Aenriched RNA isolated from various mouse organs ( Supplementary  Fig. 11 ), suggesting that sVegfr-2 might have functions outside of the eye. sVegfr2 mRNA was abundant in the alymphatic epidermis of the skin as well as in the hair follicles of wild-type mice (Fig. 4a) . sVegfr-2 protein was immunolocalized in the epidermis, hair follicles and, consistent with its ability to diffuse, also in the dermis of wild-type mice (Fig. 4b) . In contrast, mbVegfr-2 was expressed in the skin vasculature but not in epithelial cells or hair follicles (Supplementary Fig. 12a) . As in the cornea, Vegf-c was expressed in P0 wild-type mouse skin but was undetectable in adult skin (Supplementary Fig. 12b) . Excess VEGF-C in the skin, achieved by either transgenic overexpression or implantation of VEGF-C-overexpressing cells, leads to hyperplasia but not sprouting of lymphatic vessels 13, 40 . To determine the function of sVegfr-2 in the skin, we interbred Vegfr2 loxP/loxP mice with K14Cre mice that constitutively and uniformly express Cre recombinase in the epidermis and hair follicles 41 . This strategy specifically targets sVegfr-2, because the epidermis and hair follicles express sVegfr-2 but not mbVegfr-2. Notably, in the skin of all P0 K14Cre;Vegfr2 loxP/loxP mice, which lacked sVegfr-2 expression ( Fig. 4c) , there was marked enlargement of lymphatic vessels compared to those in the skin of littermate controls (Fig. 4d-f) . The dilated lymphatics in the skin of K14Cre-Vegfr2 loxP/loxP mice were also hyperplastic ( Fig. 4e,g) . However, the density of lymphatic structures, as quantified by branch (Fig. 4h) , just as in mouse skin exposed to excess VEGF-C 13, 40 . In contrast to the changes in lymphatic architecture, there was no increase in skin blood vessel diameter or density in K14Cre;Vegfr2 loxP/loxP mice (Fig. 4d,e) . Lack of sVegfr-2 in the skin thus recapitulates the effects of VEGF-C overexpression-lymphatic hyperplasia-supporting the concept that sVegfr-2 is an in vivo antagonist of Vegf-c. A protein immunoreactive to an antibody recognizing the amino terminus of Vegfr-2 has been detected in plasma and shown to be a surrogate biomarker of tumor growth [42] [43] [44] . However, its molecular identity (whether it is encoded by a splice variant of Vegfr2 or derived from ectodomain shedding or proteolytic cleavage of mbVegfr-2) and cellular source have been elusive. Circulating Vegfr-2 in plasma was immunoreactive to both the AA21127 and T014 antibodies but not to an antibody recognizing the carboxyl terminus of mbVegfr-2 ( Fig. 5a ), suggesting that circulating Vegfr-2 is encoded by the sVegfr2 splice variant. Mouse blood endothelial cell (BEC) lines derived from the microvasculature of the brain, pancreas, or skin all synthesized and secreted sVegfr-2, far in excess of its production by LECs (Fig. 5b,c) . sVegfr-2 was also detected by immunofluorescence using AA21127 in mouse lung microvasculature, identifying BECs as sources of plasma sVegfr-2 (Fig. 5d) . The production of antilymphangiogenic sVegfr-2 by BECs could be one of the mechanisms underlying the observation that lymphangiogenesis typically lags behind hemangiogenesis in many neovascular models. To our surprise, plasma concentrations of sVegfr-2 were significantly lower in K14Cre;Vegfr2 loxP/loxP mice compared to littermate controls (Fig. 5e ), suggesting that skin epithelium is also a source of circulating sVegfr-2. An earlier report showing that K14Cre-driven expression of recombinant soluble VEGFR-3 leads to measurable circulating levels of the engineered protein 27 supports the concept that endogenous skinderived sVegfr-2 can enter the circulation.
Human sVEGFR-2 inhibits lymphangioma cellular proliferation
We confirmed the existence of an mRNA by encoding sVEGFR-2 from human umbilical vein endothelial cells by using RT-PCR to clone Figure 5 sVegfr-2 is produced by BECs and skin epithelium and circulates in plasma. (a) Representative western blots of mouse plasma immunoprecipitated with an antibody against the amino terminus of Vegfr-2 (Vegfr-2 (N)) and immunoblotted with either the same antibody (left), antibody to the carboxyl terminus of sVegfr-2 (sVegfr-2 (C); right) or an antibody against the carboxyl terminus of mbVegfr-2 (mbVegfr-2 (C); center). (b) PCR amplification of sVegfr2 mRNA using cDNA derived from mouse LECs and mouse BECs isolated from the brain (Bend3), Skin (Py4) or pancreas (MS1). The first lane (H 2 O) shows a templatenegative control. Gapdh was the loading control (n = 5). (c) ELISA quantification of sVegfr-2 protein in the supernatant of blood and lymphatic endothelial cells (n = 3 per group). (d) Immunofluorescence of sVegfr-2 or isotype control antibody (red) and CD31 (green) in the pulmonary microvasculature. Cell nuclei are stained with DAPI. Scale bar, 50 µm. (Fig. 6a) .
As with mouse sVegfr2, this mRNA resulted from retention of intron 13 containing an in-frame termination stop codon. Translation of the truncated VEGFR2 mRNA results in a protein containing 679 amino acids with a unique 16-amino acid carboxyl-terminus sequence not present in mbVEGFR-2 and against which we generated a polyclonal antibody (AA21129, Supplementary Fig. 13 ). sVEGFR-2 was expressed in human cornea with a distribution similar to that in mice ( Fig. 6b ), suggesting that it has a similar role in maintaining an alymphatic state. We tested the potential antilymphangiogenic property of human sVEGFR-2 in vitro. Lymphangioma is a common disfiguring childhood neoplasia whose etiology is unknown. Human lymphangioma endothelial cells (LaECs) produce VEGF-C and express VEGFR-3 (refs. [45] [46] [47] , suggesting that their growth might be inhibited by disrupting this axis. Previously, we described the isolation of LaECs from axillary lymphangiomas in two human infants 47 . We found that sVEGFR-2 abolished VEGF-C-induced proliferation of both of these LaEC samples (Fig. 6c,d) , raising the noteworthy possibility that these pediatric tumors could be molecularly targeted.
DISCUSSION
As an endogenous uncoupler of the intertwined blood and lymphatic circulatory systems, sVegfr-2 represents a new molecular tool to selectively dissect the individual contributions of these parallel vasculatures in development and disease. Additionally, the identification of sVegfr-2 might enable new therapeutic strategies by selectively modulating aberrant lymphatic proliferation without causing the potential adverse effects of nonspecific antiangiogenic therapy.
The potential therapeutic value of selective lymphangiogenesis suppression is nowhere more apparent than in the setting of lymphangioma, which occurs in roughly 1 in 50 children 48 . These tumors, although classified as benign, can be locally invasive and quite disfiguring. Their pediatric preponderance highlights the need to develop selective antilymphangiogenic therapy. Our finding that sVEGFR-2 can prevent VEGF-C-induced proliferation of human lymphangioma endothelial cells raises the possibility that these pediatric tumors could be targeted on a molecular level.
Our discovery of sVEGFR-2 in the cornea endorses this tissue as a rich source of angiogenesis modulators and extends the concept of opposing molecular mechanisms regulating blood vessel growth 7 to lymphatics. Just as sVegfr-1 is required for corneal avascularity 11, 49 , we now show that sVegfr-2 is essential for corneal alymphaticity. The presence of both sVegfr-1 and sVegfr-2 in the cornea attests to the necessity of impeding both blood and lymphatic vessel growth to preserve optical clarity and relative immunological privilege. Notably, these tandem traps are generated by a common mechanism involving alternative splicing.
The unexpected finding that sVegfr-2 enhances corneal allograft survival despite not inhibiting hemangiogenesis suggests that impairment of the establishment of lymphatic vascular drainage 23, 24 alone is sufficient to enhance corneal allograft survival. Notably, the rate of allograft survival after a single local administration of sVegfr-2 was at least as high as the rate of survival induced by multiple systemic administrations of a VEGFR-3 antagonist in a previous study 25 . Apart from reducing lymphangiogenesis, it is also possible that sVegfr-2 promotes allograft survival by inhibiting Vegf-c-induced Vegfr-3 signaling in corneal dendritic cells and preventing their transmigration into the draining lymph node 25 . In addition to suggesting that sVegfr-2 administration could be a new therapeutic strategy for improving survival of corneal transplants, the most common type of solid organ transplantation, our data provide a mechanistic basis for studying the effect of specific lymphangiogenesis suppression in other transplants, such as kidney, whose rejection is associated with lymphangiogenesis 50 .
Unlike other reported endogenous inhibitors of lymphangiogenesis (collagen XVIII fragments, semaphorin 3F and transforming growth factor-β [51] [52] [53] [54] ), native sVegfr-2 is a specific and direct lymphangiogenesis inhibitor. An explanation for this specificity is that native sVegfr-2 exists as a monomer that, unlike dimeric mbVegfr-2, has poor avidity for Vegf-a. Nevertheless, we cannot exclude a minor antihemangiogenic role for sVegfr-2. Such a role might be masked by dominant effects of coexisting molecules, such as sVegfr-1, that have a much greater affinity for Vegf-a; in addition, such a role might become evident in experimental contexts where high levels of exogenous Vegf-c promote hemangiogenesis. A complete molecular understanding of the specific inhibition by endogenous sVegfr-2 of Vegf-c but not Vegf-a must await detailed structural studies of the Vegfr-2 ectodomain alone and in complexes with Vegf-a and Vegf-c. Collectively, our findings demonstrate that sVegfr-2 is a broad and nonredundant physiological regulator of lymphatic vessels. Further studies will reveal whether sVegfr-2 can arrest solid tumor lymphangiogenesis and metastasis, which can be promoted by VEGF-C overexpression [55] [56] [57] and inhibited by blocking Vegf-c activity 58, 59 .
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Accession codes. The sVegfr2 and sVEGFR2 sequences are deposited in GenBank with accession numbers EU884114 and FJ899739.
ONLINE METHODS
Mice. We purchased BALB/c, C57BL/6J and K14Cre mice from the Jackson Laboratory. We generated Vegfr2 loxP/loxP mice as described in the Supplementary Methods. LeCre mice 16 constitutively express Cre recombinase in the cornea. For all procedures, we anesthetized the mice by intraperitoneal injection of 50 mg per kg body weight ketamine hydrochloride (Fort Dodge Animal Health, Wyeth) and 10 mg per kg body weight xylazine (Phoenix Scientific). All mouse procedures were approved by the Animal Care and Use Committees at the University of Kentucky or Yokohama City University and conformed to the Association for Research in Vision and Ophthalmology Statement on Animal Research.
Conditional Vegfr2 gene ablation. We achieved embryonic conditional genetic ablation of Vegfr2 in the cornea by cross-breeding Vegfr2 loxP/loxP mice with LeCre mice 16 . Alternatively, to target Vegfr2 in the adult mouse cornea, we performed intrastromal injections of plasmids 11 containing the sequence for Cre recombinase driven by a cytomegalovirus promoter (pCre; 20 µg) into one eye and an empty plasmid (pNull; 20 µg) into the contralateral eye of Vegfr2 loxP/loxP or BALB/c mice 3 d before suture placement. To achieve embryonic conditional genetic ablation of Vegfr2 in the epidermis, we cross-bred Vegfr2 loxP/loxP mice with K14Cre mice that constitutively express Cre recombinase in the skin epidermis and hair follicle 41 .
Transmission electron microscopy. We enucleated eyes from wild-type and LeCre;Vegfr2 loxP/loxP mice and fixed them in 3.5% glutaraldehyde and 4% paraformaldehyde for 2 h followed by preparation of uranyl acetate-and lead citrate-stained ultrathin sections for transmission electron microscopy studies (Phillips Biotwin).
Corneal injury. We placed two intrastromal 11-0 sutures (Mani) in the mouse cornea 180° from each other. We placed all sutures in the midpoint between the limbus and the corneal apex and left them in place for up to 14 d. We injected plasmids coding for Cre and mouse sVegfr-2 (psVegfr-2) for in vivo enforced expression studies as shown previously 11 . To block Vegfr-3 activity, we performed daily intraperitoneal injections of the Vegfr-3 tyrosine kinase inhibitor (MAZ51, EMD Chemicals, 8 mg per kg body weight) in pCre-treated Vegfr2 loxP/loxP mice after corneal suture placement for 14 consecutive d. We administered vehicle only (DMSO) as a control treatment.
Vegf-C neutralization. We performed intrastromal injections of rabbit neutralizing antibody to Vegf-c (Angio-Proteomie, pV1006R-r, 16 µg) into one eye and control rabbit IgG (16 µg) into the contralateral eye on the day of suture placement and every 3 d thereafter for 14 d.
VEGFR-2 phosphorylation assay. We cultured porcine aortic endothelial cells stably transfected with VEGFR-2 (PAE-KDR cells, Sibtech) in DMEM (Invitrogen) containing 10% FBS, penicillin G (100 U ml −1 ), streptomycin sulfate (0.1 mg ml −1 ) (all from Sigma Aldrich) at 37 °C, 10% CO 2 and 90% room air. Upon attaining 80% confluence, we serum-starved these cells for 24 h, after which time we exposed them to VEGF-A (R&D Systems, 2.5 nM) or medium alone (negative control) and monomeric sVEGFR-1 (Reliatech, 15 nM), monomeric sVEGFR-2 (Reliatech, 75 nM), dimeric VEGFR2-Fc (R&D Systems, 75 nM) or IgG-Fc control (Jackson ImmunoResearch, 75 nM) for 15 min. We processed the lysates in RIPA buffer (Sigma-Aldrich), resolved the proteins by 8% SDS-PAGE and transferred them to nitrocellulose membranes. We performed immunoblotting with a rabbit antibody specific for phosphorylated VEGFR-2 (1 in 500, Upstate, 36-019), and we assessed loading with antibodies specific for VEGFR-2 (1 in 1,000, R&D Systems, AF357) and Vinculin (1 in 2,000, Sigma, V4139).
Silver staining. We resolved VEGFR-2-Fc or sVEGFR-2 by 10% SDS-PAGE and stained the gels with SilverSNAP Stain (Pierce) according to the manufacturer's instructions.
Immunomorphometric analyses. We performed immunostaining and flat mounting as previously shown 11 with rabbit antibody specific for mouse Lyve-1 (Abcam; 1 in 333), rat antibody specific for mouse CD31 (BD Biosciences;
